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Abstract Gastric cancer is caused by both genetic and
environmental factors. A woman who suffered from
recurrent candidiasis throughout her life developed diffuse-
type gastric cancer at the age of 23 years. Using whole-
exome sequencing we identified a germline homozygous
missense variant in MYD88. Immunological assays on
peripheral blood mononuclear cells revealed an impaired
immune response upon stimulation with Candida albicans,
characterized by a defective production of the cytokine
interleukin-17. Our data suggest that a genetic defect in
MYD88 results in an impaired immune response and may
increase gastric cancer risk.
Keywords MYD88  Gastric cancer  Candida albicans 
Interleukin-17  Th17 response
Introduction
GC is a multifactorial disease with a low survival rate in
which both genetic and environmental factors are involved.
Infection with Helicobacter pylori is an important risk
factor for GC [1].
Approximately 1–3 % of GC cases fulfill the criteria for
Hereditary Diffuse Gastric Cancer (HDGC; MIM 137215),
a cancer predisposition syndrome characterized by early-
onset diffuse GC. In approximately 20 % of the families
fulfilling the HDGC criteria a germline mutation can be
found in the CDH1 gene encoding the E-cadherin protein
[2–4]. Recently also CTNNA1 and MAP3K6 are described
as putative gastric cancer predisposition genes [5, 6], but in
the majority of cases the underlying genetic cause remains
unknown. In this study we report the case of a 23-year-old
woman with diffuse-type GC and recurrent candidiasis, in
whom we identified a novel germline homozygous MYD88
variant.
Materials and methods
Genetic analysis of the 23-year-old gastric cancer
patient
Genomic DNA was extracted from peripheral blood cells
and hybridized to Affymetrix SNP6.0 arrays (Affymetrix,
Santa Clara, CA, USA) according to the manufacturer’s
protocol. The genotype was generated using the Birdseed
analysis software incorporated in the Affymetrix Geno-
typing Console v2.1 (Affymetrix). Detected copy number
variants (CNVs) were compared to a set of healthy con-
trols, as described previously [7], to exclude regions of
normal variation.
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Massive parallel whole-exome sequencing was per-
formed after DNA enrichment using the human SureSelect
50 Mb kit (version 2, Agilent Technologies, Santa Clara,
CA, United States) on a 5500XL SOLiD platform (Life
Technologies, Bleiswijk, The Netherlands). Reads were
mapped to the hg19 reference genome using SOLiD
BioScope software (Life Technologies) [8]. Variants were
annotated using an in-house annotation pipeline, as
described previously [8]. Briefly, from our total set of
variants we selected high-confidence (C5 variant reads
and/or C20 % variant reads) non-synonymous variants
with a SNP frequency in dbSNP (v132) below 1 % that
were present at most once in our in-house variant database
containing 2096 exomes (the majority of European ances-
try) [8].
Missense variants were considered putatively patho-
genic when the affected nucleotide was highly conserved
(PhyloP C 3.0) and if two of the following three in silico
prediction programs considered this variant deleteri-
ous/damaging: SIFT [9], PolyPhen-2 [10], and Align
GVGD [11] [all incorporated in the Alamut 2.0 software
package (Interactive Biosoftware, Rouen, France)].
Cohort screening for MYD88 variants
Our cohort of gastric cancer patients consisted of 126
additional CDH1 mutation-negative index patients that
meet one of the 2010 HDGC criteria, with the exception
that all types of GC histology were included [12]. Germline
DNA of these patients was analyzed for mutations in
MYD88 (NM_001172567.1) using either Sanger sequenc-
ing (n = 41), ion semiconductor sequencing (n = 63)
(PGM, Life Technologies) or whole-exome sequencing
(n = 22, see above). A cohort of 183 healthy individuals
from Turkish or Pakistani descent were analyzed for the
MYD88 variant using Sanger sequencing.
For Sanger sequencing the full coding sequence of
MYD88, including splice junctions, was amplified using
polymerase chain reaction (primer sequences and PCR
conditions are available on request) and screened for
mutations using Big-Dye terminator sequencing (BigDye
Terminators (v 1.1) Applied Biosystems, USA). Analysis
was performed on an ABI 3730 DNA Analyzer (Applied
Biosystems). Subsequently, data was analyzed for variants
using Chromas Lite (Technelysium, South Brisbane,
Australia).
Ion semiconductor sequencing was performed using a
custom designed multiplex Ion AmpliSeqTM PCR primer
panel (Life Technologies) according to the manufacturer’s
protocol. Briefly, for the library preparation, four DNA
samples from our gastric cancer patient cohort were pooled
equimolarly and 10 ng of DNA was used for AmpliSeq
amplification. Each pool was barcoded with Ion Xpress
Barcode adapters (Life Technologies). The barcoded
libraries were purified using Agencourt AMPure XP beads
(Beckman Coulter Genomics, High Wycombe, UK),
pooled and diluted for use in a 200-bp amplification run on
an OneTouch emulsion PCR system (Life Technologies).
Before loading onto the 316 chip, sequencing primer and
polymerase were added to the final enriched spheres.
SeqNext software (JSI Medical Systems) was used for
mapping and analysis of the data. All amplicons were
analyzed at a coverage of at least 1509. The identified
variant was validated in the individual DNA samples of the
pool using Sanger sequencing as described above.
Immunological assays
The cytokine production capacity was assessed as previ-
ously described [13]. Briefly, venous blood was collected
into EDTA tubes and primary blood mononuclear cells
(PBMCs) were isolated by density centrifugation of blood
diluted 1:1 in PBS over Ficoll-Paque (Pharmacia Biotech
AB, Uppsala, Sweden). Cells were washed three times with
PBS and resuspended in RPMI 1640 (Dutch modified)
supplemented with 50 mg/L gentamicin, 2 mM L-glu-
tamine, and 1 mM pyruvate. Cells were counted on a
Coulter Counter Z (Beckman Coulter, Mijdrecht, the
Netherlands) and adjusted to 5 9 106 cells/mL. PBMCs
(5 9 105) in a 100 lL volume were added to round-bottom
96-well plates (Greiner, Alphen a/d Rijn, the Netherlands)
and incubated with either 100 lL of culture medium
(negative control) or one of the stimuli described for 24 h
(TNFa, IL-6), 48 h (IFN-c) and/or 7 days (IL-17 and IL-
22). Cytokine production was tested after stimulation of
PBMCs with: lipopolysaccharide (LPS) derived from
E. coli (10 ng/mL), heat-killed C. albicans (105 microor-
ganisms/mL), heat-killed H. pylori (107 microorganisms/
mL), heat-killed S. aureus (107 microorganisms/mL),
recombinant IL-1b or IL-23 (100 ng/mL), and recombinant
IL-12 or IL-18 (10 ng/mL) after 24 h and 7 days. 10 %
human pooled serum was added when PBMCs were incu-
bated during 7 days. After incubation the supernatants
were stored at -20 C until assay. Experiments were
performed in duplicate.
Results
Early-onset gastric cancer patient with extensive
infectious phenotype
The patient first presented with pain in the left upper abdo-
men at the age of 23 years. She was diagnosed with an H.
pylori infection, for which eradication treatment was given.
As the abdominal pain continued, a gastroduodenoscopywas
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performed, which revealed a gastric ulcer. Histopathological
analyses of biopsies showed a signet ring cell carcinoma and
moderate chronic active, non-specific gastritis (Fig. 1a–c).
The patient was treated with neoadjuvant chemotherapy
resulting in almost complete regression of the gastric tumor
at the time of surgery (Fig. 1d).
Because of the early-onset diffuse GC the patient was
referred for genetic counseling. Family history revealed
distantly related parents of Kurdish descent, six unaffected
siblings and no other relatives with GC. Her medical his-
tory revealed that she lost her fingernails (onycholysis) at
the age of two years. Throughout her life, she suffered from
recurrent vaginal Candida albicans infections and recur-
rent fungal infections, in particular dermatophytic ony-
chomycosis, of which at clinical examination pigmented
rash could be observed in her neck, between her breasts and
at the rim of her fingernails. Her medical history was
negative for allergies and pyogenic infections.
Identification of a novel homozygous missense
variant in MYD88
The patient developed diffuse-type GC at a very young age
and therefore meets the CDH1 testing criteria [12]. CDH1
germline mutation analysis was performed, but no germline
CDH1 alterations were found by sequencing analysis of the
entire open reading frame, including intron–exon bound-
aries, or Multiplex Ligation-dependent Probe Amplifica-
tion (MLPA) of all exons. Therefore, further research on
possible underlying genetic aberrations was performed.
Copy number profiling using SNP6.0 arrays showed no
significant copy number variations, but revealed large areas
with loss of heterozygous calls, in agreement with parental
consanguinity (data not shown).
Subsequently, whole-exome sequencing on germline
DNA from the patient was performed. No putative patho-
genic mutations in other cancer predisposition genes among
which CTNNA1 and MAP3K6 were detected. The
heterozygous missense variant in PMS1 that was validated
using Sanger sequencing (Table 1) probably does not con-
tribute to the phenotype of the patient. Because the parents
were distantly related, we focused our data-analysis on
homozygous variants with a variant percentage C80 %
(n = 17). Five variants that were putatively pathogenic (one
protein-truncating variant and four missense variants) were
validated using Sanger sequencing, of which the missense
variant (c.712C[T, p.(Arg238Cys)) in the myeloid differ-
entiation primary response 88 (MYD88) genewas considered
most relevant. This variant affects a moderately conserved
nucleotide (phyloP 3.76) of a highly conserved amino acid in
Fig. 1 Signet ring cell carcinoma of the patient. Note the typical
spreading of single cells in the gastric glands (a, b) and invasive
signet ring cells between glands in the lamina propria (c).
Gastrectomy shows patchy remnants of cancer cells in the submucosa
(d cytokeratin 8.18 stain) [original magnifications 4009 (a–c); 509
(d)]
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the Toll/interleukin-1 receptor (TIR) homology domain of
the gene and is predicted to be damaging to protein function
using in silico prediction programs. For the list of all vali-
dated variants and occurrence of variation in the corre-
sponding genes in control databases, see Table 1.
Variation in the MYD88 gene in healthy controls
and an additional cohort of gastric cancer patients is
rare
To assess the variation in MYD88 in control databases, we
extracted all the germline variation in the coding region
fromMYD88 from a second in-house dataset and the Exome
Variant Server (EVS) [14]. Furthermore, we used The
Cancer Genome Atlas (containing 220 gastric adenocarci-
nomas) to determine the amount of somatic variation in the
MYD88 gene [15]. Germline and somatic variation in the
coding region of MYD88 is rare with less than 0.5 %
heterozygous missense mutations in about 8832 individuals.
The variant detected in our patient is not present in any of
the commonly used control databases nor in 183 healthy
controls from Turkish or Pakistani descent. Moreover, only
one other heterozygous MYD88 variant (c.704G[A,
p.(G235D)) was identified by targeted resequencing of the
coding regions of the gene in 126 additional patients with
early-onset and/or familial GC. In silico analyses predicted
this variant to be benign. These results indicate that variants
in MYD88 are infrequent in both controls and GC patients.
Immunological assays reveal functional relevance
of the MYD88 variant
Since MYD88 plays a central role in the immune response,
we analyzed the cytokine production of peripheral blood
mononuclear cells (PBMCs) of the patient, stimulated with
heat-killed C. albicans and H. pylori. As expected based on
the infections seen in patients with MYD88 deficiency [16],
a specific defect in the production of Th17 cytokine IL-17
(Fig. 2, left panel) was observed upon re-stimulation of the
patients’ PBMCs with C. albicans. In healthy individuals
that have been exposed to H.pylori, an enhanced IL-17
production is observed after re-stimulation of the PBMCs
with this pathogen [17]. When we performed this assay for
the patient, no difference was observed compared to con-
trols (Fig. 2, right panel). The immune response to Toll-like
receptor stimuli and S. aureuswas normal (data not shown).
Discussion
In this study we report the case of a young woman with
diffuse-type GC in which we did not find a germline
mutation in the known cancer predisposition genes likeT
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CDH1, CTTNA1 and MAP3K6 that are associated with
diffuse gastric cancer susceptibility. Using whole-exome
sequencing, we identified a novel germline homozygous
MYD88 variant, which probably explains the patient’s
vulnerability to C. albicans and other infections that might
have contributed to the development of her gastric cancer.
MYD88 plays a central role as a mediator of the innate
immune response to infections. The infectious phenotype
of autosomal recessive MYD88 deficiency (OMIM
612260) is dominated by invasive pyogenic infections and
the main bacteria isolated in cases of invasive infection are
Staphylococcus pneumoniae, S. aureus, and Pseudomonas
aeruginosa. Also fungal infections, for example caused by
the yeast C. albicans, are described in patients with
MYD88 deficiency [18]. In mice it was shown that MYD88
deficiency leads to an early and rapid development of H.
pylori-induced gastric dysplasia [19].
GC was not reported in the twenty-four patients
described with MYD88 deficiency, of which the oldest
patient was aged 20 at time of publication [16]. However,
‘classic’ MYD88 deficiency has a high mortality at an early
age, and therefore patients likely die too young to develop
GC [20]. In contrast to the functional analyses described
for these MYD88 deficiency patients, our assays indicate
that our patient suffers from a milder form of MYD88
deficiency, which matches her clinical phenotype and is
probably explained by the type of MYD88 mutation, which
to the best of our knowledge was not described before.
Therefore, we hypothesize that, in our patient, the partial
MYD88 defect causes an impaired immune response,
resulting in recurrent C. albicans infections and non-
specific gastritis increasing the risk of signet ring cell
carcinoma of the stomach wall. Whether GC is more fre-
quently diagnosed in patients with recurrent fungal infec-
tions is unknown, but it is known that patients with
simultaneous C. albicans and H. pylori infection have an
increased risk of developing gastric ulcers [21]. C. albicans
is able to degrade E-cadherin in vitro [22], which may be a
tumor initiating event in the development of gastric signet
ring cell carcinoma similar to E-cadherin inactivation by
mutations in its gene CDH1. In line with our hypothesis
that impaired immune response might lead to an increased
risk of gastric cancer, the co-occurrence of C. albicans and
signet ring cell carcinoma of the stomach was previously
described in a patient with acquired immune deficiency
syndrome [23], who as a group have a 1.5-fold increased
risk to develop GC [24]. Moreover, a tenfold increased GC
risk is seen in patients with common variable immunode-
ficiency disorders (CVIDs) [25].
Due to neoadjuvant chemotherapy the patient received
prior to surgery, no molecular analyses were possible on
resection material. Therefore, we cannot exclude that,
although this has not been described for other DGC
patients thus far, two somatic mutations in either CDH1 or
one of the recently described candidate genes CTNNA1 or
MAP3K6 [5, 6] are causal for the DGC development. The
fact that the cancer has arisen by chance can also not be
excluded, but based on the extremely young age of the
patient we consider this very unlikely.
No additional germline mutations in MYD88 were found
in our cohort of 126 patients suspected of hereditary gastric
cancer. This implies that germline mutations in MYD88 in
GC patients are rare. Rather than screening complete
cohorts of patients for this type of mutations, we suggest
more thorough anamnestic analysis of GC patients to
unravel whether a (partial) immunodeficiency could be
causal for GC development.
In conclusion, we identified a functionally relevant
homozygous missense variant in MYD88 and a defective
Th17 response in a patient with recurrent infections and
early-onset gastric cancer. The missense variant in MYD88
is the likely cause of persistent fungal infections that
Fig. 2 Immunological assays on peripheral blood mononuclear cells
(PBMCs) from the patient with the MYD88 variant. Assays revealed
an impaired immune response upon stimulation with C. albicans (left
panel), characterized by a specific defect in production of the Th17
cytokine IL-17. Immune response to Helicobacter pylori was normal
(right panel). The detection limit for the assay is indicated with the
dotted line. Values depicted are the means with standard deviation
(SD)
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ultimately may have led to the development of early-onset
gastric cancer in this patient. Future research is needed to
unravel whether such immune deficiencies are a more
common genetic risk factor for gastric cancer development.
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